<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/0B4F1C10-DAE5-4823-9898-35F841D42DBC" ns1:id="0B4F1C10-DAE5-4823-9898-35F841D42DBC"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/5D919B4E-AF94-435F-8B7E-E45CECE6089C" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/C91FDBF4-74D2-41DA-BC63-CDA9C55F558D" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/C91FDBF4-74D2-41DA-BC63-CDA9C55F558D" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2014-11-30T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/59EA357F-A583-45EC-9025-27BEAF833BAF" ns1:rel="FUND" ns1:start="2014-07-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">131677</ns2:identifier></ns2:identifiers><ns2:title>Feature display diagnostics: A new approach for a new class of medical biomarker</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>An emerging class of biomarkers important in medical diagnostics for cancer, dementia and cardiovascular disease is the chemical modification state of individual proteins. Quantitative diagnostic assays for these particular features of proteins are not available, and Badrilla proposes to develop an entirely new approach that will achieve such quantitative measurements. This will allow us to dianose cancer early using tests for these new biomarker classes. A research plan to critically evaluate the foundation of this technology is proposed. Upon completion of this research, Badrilla will have created new intellectual property which it will exploit in areas of unmet clinical need.</ns2:abstractText></ns2:project>